Division of Allergy, Asthma and Immunology, Scripps Medical Clinic Group, San Diego, California, USA.
Curr Opin Allergy Clin Immunol. 2022 Feb 1;22(1):49-54. doi: 10.1097/ACI.0000000000000796.
The aim is to describe why this review is timely and relevant. Acetylsalicylic acid exacerbated respiratory disease (AERD) is a clinically significant disease affecting approximately 7% of all asthmatics or around 1,400,000 persons in the United States alone. A large portion of these patients remain undiagnosed. This review summarizes up to date knowledge on the pathophysiology, treatment opinions and provides an expert opinion on how to approach the AERD patient.
Findings describe the main themes in the literature covered by the article. Review of the current knowledge in terms of the key cells, cytokines/chemokines contributing to the acquired disease state of AERD. It also provides clinical approach toward the AERD patient with regards to current treatment options.
Summary describes the implications of the findings for clinical practice or research. This is an up-to-date review of the current literature, with insight into how to approach the management of an AERD patient.
本综述旨在阐述其及时性和相关性。阿司匹林加重的呼吸系统疾病（AERD）是一种具有重要临床意义的疾病，在美国，大约影响所有哮喘患者的 7%，即约 140 万人。其中很大一部分患者尚未被诊断。本综述总结了目前关于病理生理学、治疗观点的最新知识，并就如何处理 AERD 患者提供了专家意见。
本综述描述了文章涵盖的文献中的主要主题。对导致 AERD 获得性疾病状态的关键细胞和细胞因子/趋化因子的当前知识进行了综述。它还提供了针对 AERD 患者的临床方法，包括当前的治疗选择。
总结描述了这些发现对临床实践或研究的意义。这是一篇关于当前文献的最新综述，深入探讨了如何处理 AERD 患者的管理问题。
Zotero 插件